Efficacy ranked last. That is the finding that should give VMAT2 inhibitor manufacturers pause: in a discrete choice experiment Teva presented at Psych Congress this week, healthcare providers treating tardive dyskinesia in patients 55 and older weighted tolerability and dosing convenience above clinical effect when choosing between therapies.
The study used a discrete choice experiment design, which forces respondents to make explicit trade-offs rather than rate attributes in isolation, producing a more realistic picture of prescribing priorities than a standard survey. For a condition managed largely with chronic suppression of involuntary movements, that methodology matters: providers treating older patients appear to be optimizing for what their patients will actually tolerate and stick with, not for peak symptom reduction on a rating scale. Teva markets Austedo (deutetrabenazine), approved for tardive dyskinesia in adults in August 2017, and the study’s framing around older patients specifically suggests a positioning effort in a segment where polypharmacy and fall risk make side-effect profiles genuinely consequential.
The competitive context is narrow. Valbenazine (Ingrezza), approved in April 2017, is the other VMAT2 inhibitor in the class, and the two drugs have spent nearly a decade competing on largely overlapping clinical profiles. Defining the prescribing decision through provider preference data, particularly in a geriatric-adjacent population where dosing schedules and adverse event burden carry extra weight, is a legible attempt to carve differentiation where head-to-head efficacy numbers offer limited separation. Whether the attribute preferences Teva identified map cleanly onto Austedo’s actual label profile is the question the source does not answer.
The data were presented as a poster, not published in a peer-reviewed journal, so the sample size and exact utility weights assigned to each attribute are not yet in the public record. The number to track from here is how Teva deploys this preference evidence in payer submissions and formulary negotiations, where real-world tolerability arguments in older patients can shift tier placement more reliably than clinical trial endpoints alone.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
